120276-59-7

Basic information

• Product Name: 3-Chloro-6-chloromethylpyridazine
• Synonyms: 3-Chloro-6-chloromethylpyridazine;3-Chloro-6-pyridazinylmethyl chloride;Pyridazine, 3-chloro-6-(chloroMethyl)-;EOS-60690
• CAS NO: 120276-59-7
• Molecular Formula: C₅H₄Cl₂N₂
• Molecular Weight: 235.928
• Mol File: 120276-59-7.mol
• Article Data: 19

Chemical Properties

• Appearance: /
• Density: 1.410
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 3-Chloro-6-chloromethylpyridazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Chloro-6-chloromethylpyridazine(120276-59-7)
• EPA Substance Registry System: 3-Chloro-6-chloromethylpyridazine(120276-59-7)

Safety Data

• Hazardous Substances Data: 120276-59-7(Hazardous Substances Data)

Usage

Chemical Properties

Colorless liquid

Uses

3-Chloro-6-chloromethylpyridazine is used as a reagent in the synthesis of functionalized tetrahydro(ethano)triazolo[3,4-a]phthalazines as selective GABAA receptor agonists at the α3 subunit.

Upstream product

• 1121-79-5 3-chloro-6-methylpyridazine 
• 87-90-1 trichloroisocyanuric acid 
• 1011487-94-7 (6-chloropyridazin-3-yl)methanol 

Downstream Products

• 948996-03-0 C₁₃H₈ClN₃O₂ 
• 1186482-47-2 5-(6-chloro-pyridazin-3-ylmethyl)-2-(2-fluoro-phenyl)-5H-imidazo[4,5-d]pyridazine 
• 1186482-08-5 5-((6-chloropyridazin-3-yl)methyl)-2-(2,3-difluorophenyl)-5H-imidazo[4,5-d]pyridazine 
• 1000787-75-6 5-((6-(2,4-bis(trifluoromethyl)phenyl)pyridazin-3-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine 
• 1000787-76-7 5-[6-chloro-pyridazin-3-ylmethyl]-2-(2-fluoro-phenyl)-5H-imidazo[4,5-c]pyridine 
• 909401-21-4 2-(6-chloropyridazin-3-yl)acetonitrile 

Relevant articles and documents

Benzimidazole derivatives, preparation methods and uses theirof

The present invention relates to benzimidazole compounds useful in treating for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention of one or more symptoms of cancer, transplant rejections. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK4 and/or CDK6, using the compounds provided herein.

Imidazopyridazine hepatitis C virus polymerase inhibitors. Structure-activity relationship studies and the discovery of a novel, traceless prodrug mechanism

By reducing the basicity of the core heterocycle in a series of HCV NS5B inhibitors, the hERG liability was reduced. The SAR was then systematically explored in order to increase solubility and enable dose escalation while retaining potency. During this e

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.